Results 131 to 140 of about 2,434,139 (259)

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Single‐Cell Profiling Links T‐Cell Accumulation and TH2/TH17 Dynamics to Eosinophilic Esophagitis (EoE) Activity in Children

Allergy, EarlyView.
Active EoE is associated with more and deeper epithelial eosinophil, mast cell, and T cell infiltration; inactive EoE resembles controls. During remission, PPI treatment leaves more tissue resident CD3+ T‐cells than TS. In active EoE, TH2 cells, IL‐10hi Tregs, and CD8+ cytotoxic T cells are enriched, while TH17 cells are relatively depleted.
Hannes Hoelz, Matthias Tobias Warkotsch, Simon Buehler, Tim Faro, Sabrina Wagner, Valeriia Andrieieva, Alisia Beckmann, Anja Jurk, Marie‐Luise Frank, Guido Piontek, Kolja Siebert, Sebastian Jarosch, Sibylle Koletzko, Helga Paula Török, Christoph Walz, Martina Rudelius, Katja Steiger, Dirk Busch, Tobias Schwerd   +18 more
wiley   +1 more source

Eosinophilic Gastrointestinal Disorders Pathology

, 2018
Eosinophilic gastrointestinal disorders (EGID) are characterized pathologically by excess eosinophils in mucosal biopsies of one or multiple sites in the gastrointestinal (GI) tract, simultaneously or sequentially.
Kelley Capocelli, Margaret H. Collins, Guang-Yu Yang   +2 more
core   +1 more source

Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition

Allergy, EarlyView.
This study aimed to assess diagnostic delay among patients with eosinophilic granulomatosis with polyangiitis (EGPA) and identify clinical characteristics associated with delayed recognition. EGPA diagnosis was delayed by nearly five years from symptom onset in this single‐center cohort.
Vani Mulkareddy, Kalena Liu, Shreya Mandloi, Kelsey Limage, Samuel R. Shing, Gurston G. Nyquist, Jessica Most, David Kennedy, Elina Toskala, Damaris Pena‐Evertz   +9 more
wiley   +1 more source

Biologic Therapies Targeting Eosinophilic Gastrointestinal Diseases. [PDF]

Intern Med, 2023
Oshima T.
europepmc   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

Allergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, Roxane Labrosse, Thomas Eiwegger, Philippe Bégin   +12 more
wiley   +1 more source

Non-oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically.

, 2022
BACKGROUND: Non-oesophageal gastrointestinal eosinophilic diseases (EGID) are considered rare. However, low disease awareness among clinicians and pathologists may contribute to underdiagnosis.
Dellon, Evan S, Turner, Kevin O, Genta, Robert M   +2 more
core  

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy. Methods This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy.
Klementyna Łyżwa, Magdalena Chojnowska‐Wójtowicz, Wioletta Zagórska, Marek Kulus, Katarzyna Grzela   +4 more
wiley   +1 more source

Impact of Upper Gastrointestinal Involvement on Clinical Outcomes in Paediatric Inflammatory Bowel Disease

Acta Paediatrica, EarlyView.
ABSTRACT Aim The aim of this study was to assess the clinical implications of upper gastrointestinal (UGI) involvement in paediatric inflammatory bowel disease (IBD). Methods This retrospective cohort study included children diagnosed with IBD between 2010 and 2023, who underwent a UGI endoscopic evaluation at diagnosis and were followed for at least ...
Ofek Aloni, Adi Anafy, Hadar Moran‐Lev, Achiya Amir, Alma Ziv, Reut Doyev, Tut Galai, Shlomi Cohen, Anat Yerushalmy‐Feler   +8 more
wiley   +1 more source

Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial

Alimentary Pharmacology &Therapeutics, EarlyView.
Dupilumab improved all histological, symptomatic, and endoscopic outcomes assessed at Week 24 versus placebo in patients with eosinophilic oesophagitis, regardless of demographics, disease characteristics, treatment history, or type 2 inflammatory disease comorbidities.
Evan S. Dellon, Marc E. Rothenberg, Jonathan M. Spergel, Albert J. Bredenoord, Antonella Cianferoni, Changming Xia, Margee Louisias, Allen Radin   +7 more
wiley   +1 more source